Conjunctival Posttransplantation Lymphoproliferative Disorder

Walton, R. Christopher; Onciu, Mihaela; Irshad, Farhan A.; Wilson, Terry D.

doi:10.1016/j.ajo.2007.01.038

Cited by 9 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The importance of the study was that the detected types were the same in (23). In addition, the presence of EBV has been convincingly demonstrated in lymphocytic infiltrations of conjunctiva (24,25). However, to our knowledge, there have been no reports linking EBV with pterygium.…”

Section: Discussionmentioning

confidence: 80%

Investigation of Human Papillomavirus and Epstein-Barr Virus DNAs in Pterygium Tissue

Otlu

Emre

Türkçüoğlu

et al. 2009

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 80%

Investigation of Human Papillomavirus and Epstein-Barr Virus DNAs in Pterygium Tissue

Otlu

Emre

Türkçüoğlu

et al. 2009

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“… 4 , 5 A few case reports also described the possibility of an orbital involvement. 6 , 7 In the literature, posterior involvement includes vitritis, 8 , 9 subretinal masses 5 , 10 and optic disc swelling. 5 , 10 , 11 …”

Section: Discussionmentioning

confidence: 99%

Epstein-Barr virus induced post-transplant lymphoproliferative disorder presenting with unilateral retinal involvement

Adam

Philippakis

Galy

et al. 2021

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

Purpose Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of disorders associated with Epstein Barr Virus infection in up to 80% of cases in the setting of pharmacologic immunosuppression following hematopoietic stem cell or solid organ transplantation. Ocular involvement is a rare finding in PTLD. Observation We report the case of a 38-year-old man who presented with unilateral retinal infiltrates as first manifestation of PTLD relapse. Diagnosis relied on the presence of EBV DNA in anterior chamber fluids and vitrectomy that showed the presence of a B cell clone. Systemic relapse of PTLD was detected 12 weeks after retinal findings. Treatment of ocular disease included systemic injections of rituximab and intravitreal injections of methotrexate, halting the extension of retinal infiltrates. Conclusion Ocular involvement in PTLD is rare and needs to be acknowledged because it can precede a systemic relapse of the hematological condition.

show abstract

“…Although PTLD is one of the most common conditions occurring after solid organ transplantation, ocular PTLD is very rare with only 19 cases reported in the literature (Table I). Bilateral involvement occurred in around half of the cases [1,4,[9][10][11][12][13]15]. The time interval from transplantation to ocular PTLD varied from 3 months to 10 years.…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of intraocular post‐transplant lymphoproliferative disorder with intravenous rituximab

Yeung

Loong

et al. 2014

Pediatric Blood & Cancer

View full text Add to dashboard Cite

We reported a rare case of intraocular post-transplant lymphoproliferative disorder (PTLD) arising in a 3-year-old liver transplant recipient who had a prior history of systemic PTLD. The first PTLD entered remission after treatment with intravenous rituximab and withdrawal of immunosuppressants. One year after remission, she presented with granulomatous uveitis and iris nodules in the right eye. Iris biopsy confirmed recurrence of intraocular PTLD, which resolved completely after a second course of intravenous rituximab.

show abstract

Conjunctival Posttransplantation Lymphoproliferative Disorder

Cited by 9 publications

References 4 publications

Investigation of Human Papillomavirus and Epstein-Barr Virus DNAs in Pterygium Tissue

Investigation of Human Papillomavirus and Epstein-Barr Virus DNAs in Pterygium Tissue

Epstein-Barr virus induced post-transplant lymphoproliferative disorder presenting with unilateral retinal involvement

Successful treatment of intraocular post‐transplant lymphoproliferative disorder with intravenous rituximab

Contact Info

Product

Resources

About